Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/17085
Title: | FAST-1 antisense RNA epigenetically alters FXN expression |
Authors: | Pook, M Mikaeili, H Sandi, M Bayot, A Al-Mahdawi, S |
Keywords: | Friedreich ataxia;FRDA;Frataxin;FXN;FXN antisense transcript (FAST-1),;Heterochromatin, epigenetic silencing |
Issue Date: | 21-Nov-2018 |
Publisher: | Nature Research |
Citation: | Mikaeili, H., Sandi, M., Bayot, A. et al. (2018) 'FAST-1 antisense RNA epigenetically alters FXN expression', Scientific Reports, 8, 17217, pp. 1 - 11. doi: 10.1038/s41598-018-35639-2. |
Abstract: | Copyright © The Author(s) 2018. Friedreich ataxia (FRDA) is a multisystem genetic disorder caused by GAA repeat expansion mutations within the FXN gene, resulting in heterochromatin formation and deficiency of frataxin protein. Elevated levels of the FXN antisense transcript (FAST-1) have previously been detected in FRDA. To investigate the effects of FAST-1 on the FXN gene expression, we first stably overexpressed FAST-1 in non-FRDA cell lines and then we knocked down FAST-1 in FRDA fibroblast cells. We observed decreased FXN expression in 3 each FAST-1 overexpressing cell type compared to control cells. We also found that FAST-1 overexpression is associated with both CCCTC-Binding Factor (CTCF) depletion and heterochromatin formation at the 5′UTR of the FXN gene. We further showed that knocking down FAST-1 in FRDA fibroblast cells significantly increased FXN expression. Our results indicate that FAST-1 can act in Trans in a similar manner to the cis-acting FAST-1 overexpression that has previously been identified in FRDA fibroblasts. The effects of stably transfected FAST-1 expression on CTCF occupancy and heterochromatin formation at the FXN locus suggest a direct role for FAST- 1 in the FRDA molecular disease mechanism. Our findings also support the hypothesis that inhibition of FAST-1 may be a potential approach 40 for FRDA therapy.1 in the FRDA molecular disease mechanism. Our findings also support the hypothesis that inhibition of FAST-1 may be a potential approach for FRDA therapy. |
URI: | https://bura.brunel.ac.uk/handle/2438/17085 |
DOI: | https://doi.org/10.1038/s41598-018-35639-2 |
ISSN: | 2045-2322 |
Other Identifiers: | 17217 |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 1.68 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License